Monopar Therapeutics Inc. (NASDAQ:MNPR) Expected to Post Earnings of -$0.18 Per Share

Wall Street analysts expect Monopar Therapeutics Inc. (NASDAQ:MNPR) to announce earnings of ($0.18) per share for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Monopar Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.16) and the lowest estimate coming in at ($0.20). Monopar Therapeutics posted earnings per share of ($0.19) in the same quarter last year, which would indicate a positive year-over-year growth rate of 5.3%. The company is scheduled to issue its next earnings report on Thursday, March 24th.

On average, analysts expect that Monopar Therapeutics will report full-year earnings of ($0.70) per share for the current financial year, with EPS estimates ranging from ($0.72) to ($0.67). For the next fiscal year, analysts anticipate that the company will post earnings of ($1.22) per share, with EPS estimates ranging from ($1.58) to ($0.91). Zacks’ EPS averages are a mean average based on a survey of research analysts that that provide coverage for Monopar Therapeutics.

Monopar Therapeutics (NASDAQ:MNPR) last issued its quarterly earnings results on Friday, November 12th. The company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.02.

MNPR has been the subject of several analyst reports. HC Wainwright began coverage on shares of Monopar Therapeutics in a research note on Monday, November 1st. They issued a “buy” rating and a $9.00 target price for the company. Zacks Investment Research downgraded shares of Monopar Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, October 20th.

Several large investors have recently bought and sold shares of the company. Geode Capital Management LLC raised its position in Monopar Therapeutics by 9.0% during the second quarter. Geode Capital Management LLC now owns 28,761 shares of the company’s stock valued at $169,000 after acquiring an additional 2,367 shares in the last quarter. Royal Bank of Canada bought a new position in shares of Monopar Therapeutics in the first quarter valued at approximately $57,000. Citadel Advisors LLC acquired a new stake in shares of Monopar Therapeutics in the first quarter worth $77,000. Finally, Vanguard Group Inc. grew its stake in shares of Monopar Therapeutics by 116.2% in the second quarter. Vanguard Group Inc. now owns 97,462 shares of the company’s stock worth $574,000 after acquiring an additional 52,392 shares during the last quarter. Institutional investors own 1.48% of the company’s stock.

Shares of MNPR stock traded up $0.20 on Thursday, hitting $4.71. The stock had a trading volume of 11,312 shares, compared to its average volume of 116,200. The firm has a market capitalization of $59.30 million, a price-to-earnings ratio of -6.54 and a beta of 1.04. The stock’s 50 day moving average is $4.86 and its 200-day moving average is $5.23. Monopar Therapeutics has a 52-week low of $4.44 and a 52-week high of $17.01.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing proprietary therapeutics to enhance clinical outcomes for cancer patients in the United States. It is involved in developing Validive, a clonidine mucobuccal tablet that is in Phase 2b/3 clinical trial for the treatment of radiation induced severe oral mucositis in oropharyngeal cancer patients; Camsirubicin, a topoisomerase II-alpha targeted analog of doxorubicin engineered to retain anticancer activity and for minimizing toxic effects on the heart, which is in Phase 2 clinical trial; and MNPR-101, a humanized monoclonal antibody for the treatment of advanced cancers and severe COVID-19 that is in preclinical stage.

Recommended Story: Google Finance

Get a free copy of the Zacks research report on Monopar Therapeutics (MNPR)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Monopar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Monopar Therapeutics and related companies with's FREE daily email newsletter.